Vázquez-Alonso F, Puche-Sanz I, Sánchez-Ramos C, Flores-Martín J, Vicente-Prados J, Cózar-Olmo J M
Department of Urology, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain.
Case Rep Oncol Med. 2012;2012:726424. doi: 10.1155/2012/726424. Epub 2012 Sep 11.
Primary renal lymphoma (PRL) is a rare disease of which the etiology and pathogenesis remain controversial, and there is currently no standard treatment for it. We present the results of a long-term followup of two patients who were diagnosed with PRL and treated with cyclophosphamide, adriamycin, vincristine, prednisolone and rituximab (CHOP + R) regimen. Both patients reached a complete response, and there is no evidence of recurrence after 4.5- and 5-year followup periods. Based on our experience and other recently published studies, we recommend the combination of CHOP + rituximab as the elective treatment for this disease. To our knowledge, this is the longest followup period with a complete response that has been reported with this modality of treatment.
原发性肾淋巴瘤（PRL）是一种罕见疾病，其病因和发病机制仍存在争议，目前尚无标准治疗方案。我们报告了两名被诊断为PRL并接受环磷酰胺、阿霉素、长春新碱、泼尼松龙和利妥昔单抗（CHOP + R）方案治疗的患者的长期随访结果。两名患者均达到完全缓解，在4.5年和5年的随访期后均无复发迹象。基于我们的经验和其他近期发表的研究，我们推荐CHOP + 利妥昔单抗联合方案作为该病的选择性治疗方法。据我们所知，这是采用这种治疗方式报道的完全缓解后的最长随访期。
